- Home
- LSF vs VTGN Comparison
LSF vs VTGN Comparison
Compare LSF & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | VTGN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 21.8M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LSF | VTGN |
|---|---|---|
| Price | $2.76 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $6.00 | $0.90 |
| AVG Volume (30 Days) | 43.0K | ★ 482.4K |
| Earning Date | 05-06-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,889,286.00 | N/A |
| Revenue This Year | $40.85 | $124.49 |
| Revenue Next Year | $28.72 | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.43 |
| 52 Week High | $7.94 | $5.14 |
Technical Indicators
Market Signals| Indicator | LSF | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 51.74 |
| Support Level | $2.41 | $0.57 |
| Resistance Level | $3.12 | $0.66 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 92.98 | 78.12 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.